[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100168260":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":34,"centralContacts":25,"locations":38,"responsibleParty":50,"collaborators":25,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":25,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":25,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":77,"whyStopped":25,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Janssen Research & Development, LLC","INDUSTRY",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment Sequence AB","EXPERIMENTAL","The study consists of 2 treatment periods (A and B). Each treatment period wiill be separated by a washout period of 10-15 days.",[13,14,15],"Drug: Treatment A: Canagliflozin tablet","Drug: Treatment A: Metformin IR tablets","Drug: Treatment B: Canagliflozin\u002Fmetformin fixed dose combination tablets",{"label":17,"type":10,"description":11,"interventionNames":18},"Treatment Sequence BA",[13,14,15],[20,26,30],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Treatment A: Canagliflozin tablet","Type=exact number, unit=mg, number=100, form=tablet, route=oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period A.",[9,17],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Treatment A: Metformin IR tablets","Type=exact number, unit=mg, number=850, form=tablet, route=oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period A.",[9,17],{"type":21,"name":31,"description":32,"armGroupLabels":33,"otherNames":25},"Treatment B: Canagliflozin\u002Fmetformin fixed dose combination tablets","Type=exact number, unit=mg, number=50\u002F850, form=tablet, route=oral use. Two canagliflozin\u002Fmetformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period B.",[9,17],[35],{"name":36,"affiliation":5,"role":37},"Janssen Research & Development, LLC L.LC. Clinical Trial","STUDY_DIRECTOR",[39],{"facility":25,"status":25,"city":40,"state":41,"zip":25,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":25},"Lincoln","Nebraska","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-96.66696,40.8,{"lat":48,"lon":47},{"type":51,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100168260","phase-1-a-study-to-assess-the-bioequivalence-of-2-fixed-dose-combination-tablets-of-canagliflozin-and-metformin-immediate-release-ir-with-respect-to-the-individual-components-of-canagliflozin-and-metformin-ir-tablets-in-healthy-volunteers-100168260",false,"NCT01463774","A Study to Assess the Bioequivalence of 2 Fixed Dose Combination Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers","Pivotal BE CANA\u002FMET IR FDC - Low Strength","Inclusion Criteria:\n\n* Body mass index (BMI) between 18.5 and 30 kg\u002Fm² inclusive and a body weight of not less than 50 kg\n\nExclusion Criteria:\n\n* History of or current medical illness, abnormal values for hematology or clinical chemistry laboratory tests, or abnormal physical examination, vital signs or 12-lead electrocardiogram (ECG) deemed to be clinically significant by the Investigator",true,"ALL","19 Years","55 Years",{"count":64,"type":65},74,"ACTUAL","INTERVENTIONAL",[68],"PHASE1","The purpose of this study is to evaluate the bioequivalence of a fixed dose combination tablet of canagliflozin and metformin immediate release (IR) in comparison with the individual components of canagliflozin and metformin IR.",[71],"Healthy",[73,74,75,76],"Healthy Volunteers","Bioequivalence","Canagliflozin (JNJ-28431754)","Metformin","COMPLETED","2012-11-20",{"date":80,"type":81},"2012-11-21","ESTIMATED",{"date":83,"type":25},"2011-09",{"date":85,"type":65},"2011-12",{"name":5,"class":6},1]